Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Astellas Pharma
Woman and Man Max 99 years
Astellas Pharma Korea, Inc
Update Il y a 4 ans
Trial on the therapeutic effect of Tacrolimus in combination with low dosage corticosteroids compared with high dosage corticosteroids only, in patients with minimal change necrotic syndrome
To compare the therapeutic effect of tacrolimus (Prograf®) in combination with low-dose corticosteroid with high-dose corticosteroid alone in patients with minimal change nephrotic syndrome after a 24...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V. by August 2005)
Update Il y a 4 ans
A Phase II, Multicenter, Open-Label Study of YM155 in Patients With Advanced Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) Who Have Failed One or Two Prior Lines of Therapy, at Least One of Which Contained a Platinum Agent
To evaluate the efficacy of YM155 based on objective tumor response rate (CR+PR) in patients with measurable disease based on RECIST criteria
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN STABLE HEART TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF® BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT EVEROLIMUS
The primary objective of this study is to compare two immunosuppressive therapy regimens with respect to their influence on estimated Glomerular Filtration Rate (eGFR) at 52 weeks after conversion to ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Global Development, Inc
Update Il y a 4 ans
This multi center Phase III clinical trial will evaluate impact of maintenance therapy (maintain the response achieved during the first course of treatment) with the FLT3 (FMS-like tyrosine kinase 3) inhibitor gilteritinib on the RFS (Relapse free survival) of participants with FLT3/ITD AML (FMS-like tyrosine kinase 3 / Internal tandem duplication Acute myeloid leukemia) who have successfully undergone allogeneic transplant. Este ensayo clínico de Fase III, multicéntrico, va a evaluar el impacto del tratamiento de mantenimiento (para mantener la respuesta alcanzada durante el primer ciclo de tratamiento) con gilterinib, un inhibidor de la FLT3 (FMS-like tyrosine kinase 3), sobre la RFS (relapse free survival) de participantes con leucemia mieloide aguda con FLT3/ITD (FMS-like tyrosine kinase 3 / Internal tandem duplication) que han sido sometidos con éxito a un alotrasplante en este estudio
The primary objective is to compare relapse-free survival (RFS) between participants with FLT3/ITD AML in CR1 who undergo HCT and are randomized to receive gilteritinib or placebo beginning after the ...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Astellas Pharma Global Development, Inc
Update Il y a 4 ans
Study to evaluate the efficacy and safety of combined use of tamsulosin and mirabegron in men who have enlarged prostate and an overactive bladder Eine doppelblinde, randomisierte, plazebokontrollierte multizentrische Phase IV-Studie zur Untersuchung der Wirksamkeit, Sicherheit und Verträglichkeit von Mirabegron bei männlichen Patienten mit überaktiver Blase (OAB), die wegen Symptomen des unteren Harntraktes (LUTS) im Zusammenhang mit einer benignen Prostatahyperplasie (BPH) mit dem Alpha-Blocker Tamsulosinhydrochlorid behandelt werden
To study the efficacy of mirabegron versus placebo in men with OAB symptoms while taking tamsulosin hydrochloride for LUTS due to BPH.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN WITH SIMPLIFIED BLADDER TRAINING VERSUS SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN ALONE IN A PROSPECTIVE, RANDOMIZED, PARALLEL GROUP, OVERACTIVE BLADDER SYMPTOM STUDY
To assess the efficacy of solifenacin succinate 5mg od plus simplified bladder training compared with solifenacin succinate 5mg od alone at 8 weeks in subjects with overactive bladder symptoms
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A study to investigate how solifenacin fluid is taken up, how long it stays in the body and how effective and safe it is in treating children aged from 6 months to less than 5 years with symptoms of neurogenic detrusor overactivity
To evaluate the long-term efficacy, safety, and pharmacokinetics (PK) of solifenacin succinate suspension after multiple dose administration.
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Astellas Pharma Global Development, Inc (APGD)
Update Il y a 4 ans
A Multinational study, Phase 3, Randomized, Double-blind, and controlled against a Placebo that studies the Efficacy and the Safety of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by radiographic progression-free survival (rPFS) based on central review
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
A study in which multiple applications of Qutenza are investigated in patients with nerve pain
To assess the safety of repeated treatments of QUTENZA in subjects with peripheral neuropathic pain.
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
Enzalutamide Treatment of Metastatic Castration-Resistant Prostate Cancer Patients after Abiraterone Acetate Tratamiento con enzalutamida del cáncer de próstata progresivo y metastásico resistente a la castración tras acetato de abiraterona
Evaluation of radiographic progression-free survival (rPFS) Evaluar la supervivencia sin progresión radiográfica (SSPr)
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next